Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients

NCT05039190 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Myasthenia Gravis

Interventions

DRUG: HBM9161 Injection (680mg)
DRUG: Placebo

Sponsor

Harbour BioMed (Guangzhou) Co. Ltd.